ClinicalTrials.gg
CompletedNCT03894969Updated Sep 23, 2024Results posted

Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine

A Phase 2 interventional study of GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E and Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A) in Respiratory Disorders, sponsored by GlaxoSmithKline. Completed at 14 sites in 5 countries. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
541
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Respiration Disorders by GlaxoSmithKline — none open to participants now, 1 under way, 1 of them phase 3. Respiration Disorders · GlaxoSmithKline.

Enrollment
4th of 19
541 · median 120
Started
2019
the only one that year
Phase 2
4 of 22
none open now
Registered
19th of 22
by date

Among the 22 studies in Respiration Disorders by GlaxoSmithKline, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 2, and was the 19th registered.

Respiration Disorders

359 studies on the registry are indexed under Respiration Disorders; 64 are open to participants now.

Browse Respiration Disorders studies →

Open to participants now

None of the 22 studies in Respiration Disorders by GlaxoSmithKline is open now. The open studies under Respiration Disorders, anywhere →

Who these studies take

Of the 45 Respiration Disorders studies recruiting now, 27 (60%) set no upper age limit and 13 (29%) stop at 75 or younger; 15 take children under 18; 21 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Respiration Disorders by GlaxoSmithKline as a file.
02

Study summary

This study will provide information regarding the sequential administration of two vaccines adjuvanted with AS01.

The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when administered sequentially after Shingrix vaccine and to compare to the immunogenicity of NTHi-Mcat vaccine administered alone. This study will also provide information regarding whether a specific time period is required between the administration of these two different vaccines containing the same adjuvant- AS01 components.

The population of this study will include healthy smokers and ex-smokers of 50 to 80 years of age which will be used as a proxy for the COPD population.

03

Conditions studied

  • Respiratory Disorders

Keywords

  • Immunogenicity
  • Chronic obstructive pulmonary disease (COPD)
  • Non-typeable Haemophilus influenza
  • Moraxella catarrhalis
  • Shingrix
  • Herpes Zoster
  • Adjuvanted vaccines
  • Safety
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
  • Written obtained from the subject prior to performance of any study specific procedure.
  • A male or female between, and including, 50 years and 80 years of age at the time of the first vaccination.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Current or former smoker with a cigarette smoking history ≥10 pack-years.
  • Female subjects of non- may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject: has practiced adequate for 30 days prior to vaccination, and; has a negative pregnancy test on the day of vaccination, and; has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Medical conditions
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • History of potential immune-mediated disease (pIMD). Note: If the subject has any condition on the list of pIMDs specified in the protocol, they must be excluded unless the aetiology is clearly documented to be non-immune mediated.

The investigator will exercise his/her medical and scientific judgement in deciding whether other diseases have an origin and thus meet the exclusion criteria.

  • Diagnosis of regardless of severity.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines. Additionally, consider allergic reactions to other material or equipment related to study participation (such as materials that may possibly contain latex -gloves, syringes, etc).
  • Has significant disease (including significant psychological disorders), in the opinion of the investigator, likely to interfere with the study and/or likely to cause death within the study duration.
  • History of or current condition preventing intramuscular injection as bleeding or coagulation disorder.
  • within previous 5 years (excluding non-melanoma skin cancer) or lymphoproliferative disorders.
  • Prior/concomitant therapy
  • Use of any or non-registered product (drug or vaccine) other than the study vaccines during the period starting 30 days before the first dose of study vaccine (Day -29 to Day 1), or planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of vaccine administration, with the exception of non-MF59 adjuvanted influenza vaccines and pneumococcal vaccines which may be administered ≥15 days preceding or following any study vaccine dose.

Note: For M59 adjuvanted flu vaccine and for any vaccine containing novel adjuvant refer to exclusion criteria below.

  • Planned administration/administration of a vaccine adjuvanted with the following adjuvants AS01, AS02, AS03, AS04 and MF59 in the period starting 6 months before the first dose of study vaccine, and ending at the second blood draw (i.e. approximately 1 month after the administration of the last dose of NTHi-Mcat vaccine). The following non-exhaustive list should be considered as criteria for exclusion: Prepandrix, Adjupanrix, Shingrix, Fendrix, Cervarix, FluAd, Chiromas, Gripguard.
  • Previous vaccination with any vaccine containing NTHi and/or Mcat antigens
  • Previous vaccination with Shingrix; (either registered product or participation in a previous vaccine study).
  • Previous vaccination with HZ (ZVL)) (either registered product or participation in a previous vaccine study) within the 2 months of the first study visit (Day 1).
  • Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab).
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 6 months prior to the first vaccine dose, and ending at the second blood draw. (i.e. approximately 1 month after the administration of the last dose of NTHi-Mcat vaccine). For , this will mean prednisone ≥5 mg/day (for adult subjects), or equivalent. Only topical steroids are allowed.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the first dose of study vaccine or planned administration starting from Day 1 and ending at the second blood draw (i.e. approximately 1 month after the planned administration of the second dose of NTHi-Mcat vaccine).
  • Prior/concurrent clinical study experience
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or medical device).
  • Other exclusions:
  • Pregnant or lactating female,
  • Female planning to become pregnant or planning to discontinue precautions,
  • Current alcoholism and/or drug abuse,
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study
  • Any study personnel or immediate dependents, family, or household member.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
541 participants (actual)

Study arms

  • Experimental
    Sh_NTHi-Mcat_1 Group

    Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.

    Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E · Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)

  • Experimental
    Sh_NTHi-Mcat_3 Group

    Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.

    Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E · Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)

  • Experimental
    Sh_NTHi-Mcat_6 Group

    Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.

    Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E · Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)

  • Active comparator
    NTHi-Mcat Group

    Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.

    Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E

  • Experimental
    Shingrix-Only Group

    Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.

    Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)

Interventions

  • BiologicalGSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E

    2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm

  • 2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm

06

What researchers measure

Primary outcomes

  1. Anti-Protein D (PD), Anti-Protein E (PE), Anti-type IV Pili Subunit (PilA) and Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Adjusted Geometric Mean Concentrations (GMCs), One-month Post Dose-2 of NTHi-Mcat Vaccine

    Antibody concentrations as measured by ELISA (Enzyme-linked immunosorbent assay) and expressed as adjusted (ANCOVA model) GMCs in ELISA units per milliliter (EU/mL). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively. The ANCOVA model includes study group, smoking status (current or former), age category (50-59, 60-69, 70-80 years of age) and center as factors and the antibody concentration before Dose 1 as covariate. As per protocol set (PPS) sample size was not met in Sh_NTHi_Mcat_3 and Sh_NTHi-Mcat_6 groups then timeframe was adapted as follows: At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181 in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)

    Time frame: At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181, in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)

Secondary outcomes

  1. Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, Before First NTHi-Mcat Vaccine

    GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations)

    Time frame: Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 for Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 for NTHi-Mcat group)

  2. Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, One-month Post Dose-2 of NTHi-Mcat Vaccine

    GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations) before the first dose of NTHi-Mcat vaccine

    Time frame: At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)

  3. Percentage of Seropositive Subjects for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies Before First NTHi-Mcat Vaccine

    A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI is defined using the assay lower limit of quantification (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively

    Time frame: Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)

  4. Percentage of Subjects Seropositive for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies, One-month Post Dose-2 of NTHi-Mcat Vaccine

    A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI are defined using the assay (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively

    Time frame: At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)

  5. Frequency of Specific Cluster of Differentiation 4 (CD4+) T-cells Against NTHi and Mcat Antigens for Evaluation of Cell-mediated Immune (CMI) Response, Before First Dose of NTHi-Mcat Vaccine

    Frequency of specific CD4+ T-cells was measured by flow cytometry intracellular cytokine staining (ICS) expressing at least 2 different markers among CD40 Ligand (CD40L), interleukin (IL)-2, IL-13, IL-17, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), upon in vitro stimulation

    Time frame: Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)

  6. Frequency of CD4+ T-cells Against NTHi and Mcat Antigens for Evaluation of CMI Response, at One-month Post Dose 2 of NTHi-Mcat Vaccine

    Frequency of specific CD4+ T-cells was measured by flow cytometry ICS expressing at least 2 different markers among CD40L, IL-2, IL-13, IL-17, TNF-α and IFN-γ, upon in vitro stimulation

    Time frame: At one month after second dose of NTHi-Mcat vaccine (Day 181, Day 241 and Day 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)

  7. Percentage of Subjects With Reported Solicited Local Adverse Event (AE)

    The percentage of subjects with at least one local solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed local symptoms were pain, redness and swelling. Any local injection site redness/swelling is scored as follows: diameter \>=20 milli-meters

    Time frame: During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine

  8. Percentage of Subjects With Reported Solicited General AE

    The percentage of subjects with at least one general solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed solicited general symptoms were Fatigue, Gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Chills and Fever (oral cavity or axillary route - temperature equal or higher than \[\>=\] 37.5 degrees Celsius \[°C\])

    Time frame: During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine

  9. Percentage of Subjects With Any Unsolicited AE

    An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. The percentage of subjects with at least one unsolicited AE, regardless of intensity or relationship to vaccination, during the 30-day follow-up period after any NTHi-Mcat vaccine dose are reported for each group. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event

    Time frame: During the 30-day follow-up period (i.e. day of vaccination and 29 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine

  10. Percentage of Subjects With Any Serious Adverse Event (SAE) During Epoch 001

    The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 1 up to and including Day 331, were reported for each group An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician

    Time frame: From Day 1 up to and including Day 331 (Epoch 001)

  11. Percentage of Subjects With Any Potential Immune-mediated Diseases (pIMD's) During Epoch 001

    pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From Day 1 up to and including Day 331 (Epoch 001)

  12. Percentage of Subjects With Any SAE During Epoch 002

    The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 332 up to and including Day 661, are reported for each group. An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, requires hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician.

    Time frame: From Day 332 up to and including Day 661 (Epoch 002)

  13. Percentage of Subjects With Any pIMD's During Epoch 002

    pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology

    Time frame: From Day 332 up to and including Day 661 (Epoch 002)

07

Results

Posted Sep 27, 2021

Participant flow

Participant flow — Overall Study
MilestoneSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only Group
Started13413412213516
Completed1291291181282
Not completed554714
Withdrew: Adverse event02012
Withdrew: Lost to follow-up31100
Withdrew: Withdrawal by subject21348
Withdrew: Other00003
Withdrew: Unsolicited non-serious advers event00021
Withdrew: Solicited adverse event01000

Outcome measures

PrimaryAnti-Protein D (PD), Anti-Protein E (PE), Anti-type IV Pili Subunit (PilA) and Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Adjusted Geometric Mean Concentrations (GMCs), One-month Post Dose-2 of NTHi-Mcat Vaccine

Antibody concentrations as measured by ELISA (Enzyme-linked immunosorbent assay) and expressed as adjusted (ANCOVA model) GMCs in ELISA units per milliliter (EU/mL). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively. The ANCOVA model includes study group, smoking status (current or former), age category (50-59, 60-69, 70-80 years of age) and center as factors and the antibody concentration before Dose 1 as covariate. As per protocol set (PPS) sample size was not met in Sh_NTHi_Mcat_3 and Sh_NTHi-Mcat_6 groups then timeframe was adapted as follows: At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181 in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)

Time frame:
At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181, in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)
Reported as:
Geometric mean · EU/mL
Anti-Protein D (PD), Anti-Protein E (PE), Anti-type IV Pili Subunit (PilA) and Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Adjusted Geometric Mean Concentrations (GMCs), One-month Post Dose-2 of NTHi-Mcat Vaccine
EU/mLSh_NTHi-Mcat_1 GroupNTHi-Mcat Group
Anti-PD1402.804 (1139.194 to 1727.414)1489.531 (1203.846 to 1843.014)
Anti-PE6234.827 (5053.049 to 7692.992)7032.52 (5666.105 to 8728.452)
Anti-PilA1244.373 (963.063 to 1607.854)1089.799 (840.246 to 1413.47)
Anti-UspA21022.961 (894.403 to 1169.998)941.45 (820.993 to 1079.58)
Statistical analysis
  • Sh_NTHi-Mcat_1 Group · ANCOVA · Gmc ratio: 0.942 · .95% CI 0.765 to 1.159ANCOVA model with treatment group, age category, smoking status and center as fixed effects and pre-Dose 1 log-concentration as a covariate.
  • Sh_NTHi-Mcat_1 Group · ANCOVA · Gmc ratio: 0.887 · .95% CI 0.719 to 1.093ANCOVA model with treatment group, age category, smoking status and center as fixed effects and pre-Dose 1 log-concentration as a covariate.
  • Sh_NTHi-Mcat_1 Group · ANCOVA · Gmc ratio: 1.142 · .95% CI 0.884 to 1.474ANCOVA model with treatment group, age category, smoking status and center as fixed effects and pre-Dose 1 log-concentration as a covariate.
  • Sh_NTHi-Mcat_1 Group · ANCOVA · Gmc ratio: 1.087 · .95% CI 0.948 to 1.245ANCOVA model with treatment group, age category, smoking status and center as fixed effects and pre-Dose 1 log-concentration as a covariate.
SecondaryAnti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, Before First NTHi-Mcat Vaccine

GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations)

Time frame:
Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 for Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 for NTHi-Mcat group)
Reported as:
Geometric mean · EU/mL
Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, Before First NTHi-Mcat Vaccine
EU/mLSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat Group
Anti-PD94.7 (86.2 to 104.1)105.1 (89.8 to 123)95.6 (84.5 to 108.3)105.3 (93.4 to 118.6)
Anti-PE22 (18 to 26.9)21.2 (17.6 to 25.4)18.6 (14.3 to 24.2)23.9 (19.8 to 28.9)
Anti-PilA7.8 (6.6 to 9.3)10.5 (8.2 to 13.5)9.7 (7.5 to 12.6)9.1 (7.5 to 11)
Anti-UspA2352.4 (292.5 to 424.7)343 (286.3 to 411)440.3 (343.5 to 564.5)521.4 (441 to 616.3)
SecondaryAnti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, One-month Post Dose-2 of NTHi-Mcat Vaccine

GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations) before the first dose of NTHi-Mcat vaccine

Time frame:
At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)
Reported as:
Geometric mean · EU/mL
Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, One-month Post Dose-2 of NTHi-Mcat Vaccine
EU/mLSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat Group
Anti-PD1496.7 (1272.7 to 1760.1)1504 (1209.9 to 1869.6)1539 (1277.3 to 1854.2)1683.5 (1434.5 to 1975.5)
Anti-PE5911.8 (5121.3 to 6824.3)5920.8 (4868.4 to 7200.8)6048.5 (4943.3 to 7400.8)6562.4 (5660.9 to 7607.5)
Anti-PilA1089.3 (910.3 to 1303.4)1030.6 (839.4 to 1265.3)1114.7 (864.9 to 1436.6)999.3 (830.3 to 1202.7)
Anti-UspA2926.8 (796.6 to 1078.4)942.2 (819.6 to 1083.2)1289.2 (1062.5 to 1564.5)1066.4 (946.6 to 1201.4)
SecondaryPercentage of Seropositive Subjects for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies Before First NTHi-Mcat Vaccine

A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI is defined using the assay lower limit of quantification (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively

Time frame:
Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)
Reported as:
Number · Percentage of subjects
Percentage of Seropositive Subjects for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies Before First NTHi-Mcat Vaccine
Percentage of subjectsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat Group
Anti-PD16.9 (10.7 to 25)20 (12.5 to 29.5)19.2 (10.9 to 30.1)21.8 (14.9 to 30.1)
Anti-PE57.6 (48.2 to 66.7)63.5 (53.1 to 73.1)50.7 (38.7 to 62.6)61.8 (52.6 to 70.4)
Anti-PilA38.1 (29.4 to 47.5)49 (38.6 to 59.4)47.9 (36.1 to 60)43.5 (34.7 to 52.7)
Anti-UspA2100 (96.9 to 100)100 (96.2 to 100)100 (95.1 to 100)100 (97.1 to 100)
SecondaryPercentage of Subjects Seropositive for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies, One-month Post Dose-2 of NTHi-Mcat Vaccine

A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI are defined using the assay (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively

Time frame:
At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)
Reported as:
Number · Percentage of subjects
Percentage of Subjects Seropositive for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies, One-month Post Dose-2 of NTHi-Mcat Vaccine
Percentage of subjectsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat Group
Anti-PD99.2 (95.4 to 100)97.9 (92.7 to 99.7)100 (95.1 to 100)100 (97 to 100)
Anti-PE100 (96.9 to 100)100 (96.2 to 100)100 (95.1 to 100)100 (97.1 to 100)
Anti-PilA100 (96.9 to 100)100 (96.2 to 100)100 (95.1 to 100)100 (97.1 to 100)
Anti-UspA2100 (96.9 to 100)100 (96.2 to 100)100 (95.1 to 100)100 (97.1 to 100)
SecondaryFrequency of Specific Cluster of Differentiation 4 (CD4+) T-cells Against NTHi and Mcat Antigens for Evaluation of Cell-mediated Immune (CMI) Response, Before First Dose of NTHi-Mcat Vaccine

Frequency of specific CD4+ T-cells was measured by flow cytometry intracellular cytokine staining (ICS) expressing at least 2 different markers among CD40 Ligand (CD40L), interleukin (IL)-2, IL-13, IL-17, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), upon in vitro stimulation

Time frame:
Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)
Reported as:
Mean · CD4+ T cells/million cells
Frequency of Specific Cluster of Differentiation 4 (CD4+) T-cells Against NTHi and Mcat Antigens for Evaluation of Cell-mediated Immune (CMI) Response, Before First Dose of NTHi-Mcat Vaccine
CD4+ T cells/million cellsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat Group
M catarrhalis.UspA2 - CD4+ T-cells112.945 ± 153.903101.739 ± 94.93281.578 ± 90.91992.685 ± 99.661
NTHi.PD - CD4+ T-cells89.456 ± 68.92959.522 ± 82.0636.439 ± 57.34796.893 ± 74.87
NTHi.PE - CD4+ T-cells79.838 ± 58.99946.112 ± 63.00769.546 ± 97.0980.717 ± 119.316
NTHi.PilA - CD4+ T-cells61.627 ± 53.61342.438 ± 55.57560.139 ± 51.37105.558 ± 97.618
SecondaryFrequency of CD4+ T-cells Against NTHi and Mcat Antigens for Evaluation of CMI Response, at One-month Post Dose 2 of NTHi-Mcat Vaccine

Frequency of specific CD4+ T-cells was measured by flow cytometry ICS expressing at least 2 different markers among CD40L, IL-2, IL-13, IL-17, TNF-α and IFN-γ, upon in vitro stimulation

Time frame:
At one month after second dose of NTHi-Mcat vaccine (Day 181, Day 241 and Day 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)
Reported as:
Mean · CD4+ T cells/million cells
Frequency of CD4+ T-cells Against NTHi and Mcat Antigens for Evaluation of CMI Response, at One-month Post Dose 2 of NTHi-Mcat Vaccine
CD4+ T cells/million cellsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat Group
M catarrhalis.UspA2 - CD4+ T-cells721.851 ± 457.94619.68 ± 392.1331001.839 ± 144.057735.177 ± 471.515
NTHi.PD - CD4+ T-cells632.849 ± 323.731527.26 ± 281.8271570.631 ± 1064.327742.666 ± 527.567
NTHi.PE - CD4+ T-cells565.964 ± 411.715581.338 ± 520.594888.057 ± 154.5241155.341 ± 699.841
NTHi.PilA - CD4+ T-cells332.43 ± 273.215318.46 ± 195.527333.501 ± 121.712388.282 ± 207.434
SecondaryPercentage of Subjects With Reported Solicited Local Adverse Event (AE)

The percentage of subjects with at least one local solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed local symptoms were pain, redness and swelling. Any local injection site redness/swelling is scored as follows: diameter \>=20 milli-meters

Time frame:
During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Reported Solicited Local Adverse Event (AE)
Percentage of subjectsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat Group
Erythema (mm), Dose 16 (2.6 to 11.4)15 (9.4 to 22.3)11 (6 to 18.1)12.6 (7.5 to 19.4)
Erythema (mm), Dose 212.8 (7.6 to 19.7)13.7 (8.4 to 20.8)17.9 (11.5 to 26.1)11.8 (6.8 to 18.7)
Pain, Dose 159.7 (50.9 to 68.1)69.2 (60.6 to 76.9)61 (51.6 to 69.9)63.7 (55 to 71.8)
Pain, Dose 269.9 (61.4 to 77.6)76.3 (68.1 to 83.3)72.6 (63.6 to 80.5)75.6 (67.2 to 82.8)
Swelling (mm), Dose 13.7 (1.2 to 8.5)10.5 (5.9 to 17)5.9 (2.4 to 11.8)5.2 (2.1 to 10.4)
Swelling (mm), Dose 27.5 (3.7 to 13.4)8.4 (4.3 to 14.5)6.8 (3 to 13)7.9 (3.8 to 14)
SecondaryPercentage of Subjects With Reported Solicited General AE

The percentage of subjects with at least one general solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed solicited general symptoms were Fatigue, Gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Chills and Fever (oral cavity or axillary route - temperature equal or higher than \[\>=\] 37.5 degrees Celsius \[°C\])

Time frame:
During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Reported Solicited General AE
Percentage of subjectsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat Group
Chills, Dose 111.9 (7 to 18.7)12 (7 to 18.8)16.9 (10.7 to 25)7.4 (3.6 to 13.2)
Chills, Dose 225.6 (18.4 to 33.8)26 (18.7 to 34.3)22.2 (15.1 to 30.8)16.5 (10.5 to 24.2)
Fatigue, Dose 126.1 (18.9 to 34.4)38.3 (30.1 to 47.2)39 (30.1 to 48.4)34.1 (26.1 to 42.7)
Fatigue, Dose 239.1 (30.8 to 47.9)48.1 (39.3 to 57)43.6 (34.4 to 53.1)37.8 (29.3 to 46.8)
Fever (C), Dose 11.5 (0.2 to 5.3)1.5 (0.2 to 5.3)2.5 (0.5 to 7.3)3 (0.8 to 7.4)
Fever (C), Dose 211.3 (6.5 to 17.9)8.4 (4.3 to 14.5)8.5 (4.2 to 15.2)8.7 (4.4 to 15)
Gastrointestinal symptoms, Dose 113.4 (8.2 to 20.4)13.5 (8.2 to 20.5)16.1 (10 to 24)13.3 (8.1 to 20.3)
Gastrointestinal symptoms, Dose 215.8 (10 to 23.1)15.3 (9.6 to 22.6)12.8 (7.4 to 20.3)9.4 (5 to 15.9)
Headache, Dose 120.9 (14.4 to 28.8)26.3 (19.1 to 34.7)22.9 (15.7 to 31.5)18.5 (12.4 to 26.1)
Headache, Dose 232.3 (24.5 to 41)38.2 (29.8 to 47.1)23.9 (16.5 to 32.7)22 (15.2 to 30.3)
Myalgia, Dose 120.1 (13.7 to 27.9)23.3 (16.4 to 31.4)25.4 (17.9 to 34.3)27.4 (20.1 to 35.7)
Myalgia, Dose 233.1 (25.2 to 41.8)37.4 (29.1 to 46.3)36.8 (28 to 46.2)37.8 (29.3 to 46.8)
SecondaryPercentage of Subjects With Any Unsolicited AE

An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. The percentage of subjects with at least one unsolicited AE, regardless of intensity or relationship to vaccination, during the 30-day follow-up period after any NTHi-Mcat vaccine dose are reported for each group. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event

Time frame:
During the 30-day follow-up period (i.e. day of vaccination and 29 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Any Unsolicited AE
Percentage of subjectsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat Group
Dose 113.4 (8.2 to 20.4)14.9 (9.4 to 22.1)11.5 (6.4 to 18.5)18.5 (12.4 to 26.1)
Dose 215 (9.4 to 22.3)15.3 (9.6 to 22.6)8.5 (4.1 to 15)10.9 (6.1 to 17.5)
SecondaryPercentage of Subjects With Any Serious Adverse Event (SAE) During Epoch 001

The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 1 up to and including Day 331, were reported for each group An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician

Time frame:
From Day 1 up to and including Day 331 (Epoch 001)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Any Serious Adverse Event (SAE) During Epoch 001
Percentage of subjectsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only Group
Percentage of Subjects With Any Serious Adverse Event (SAE) During Epoch 0014.5 (1.7 to 9.5)3.7 (1.2 to 8.5)2.5 (0.5 to 7)1.5 (0.2 to 5.2)6.3 (0.2 to 30.2)
SecondaryPercentage of Subjects With Any Potential Immune-mediated Diseases (pIMD's) During Epoch 001

pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From Day 1 up to and including Day 331 (Epoch 001)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Any Potential Immune-mediated Diseases (pIMD's) During Epoch 001
Percentage of subjectsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only Group
Percentage of Subjects With Any Potential Immune-mediated Diseases (pIMD's) During Epoch 0010 (0 to 2.7)1.5 (0.2 to 5.3)0.8 (0 to 4.5)0 (0 to 2.7)12.5 (1.6 to 38.3)
SecondaryPercentage of Subjects With Any SAE During Epoch 002

The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 332 up to and including Day 661, are reported for each group. An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, requires hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician.

Time frame:
From Day 332 up to and including Day 661 (Epoch 002)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Any SAE During Epoch 002
Percentage of subjectsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only Group
Percentage of Subjects With Any SAE During Epoch 0023.0 (0.8 to 7.5)4.5 (1.7 to 9.5)3.3 (0.9 to 8.2)2.2 (0.5 to 6.4)0.0 (0.0 to 20.6)
SecondaryPercentage of Subjects With Any pIMD's During Epoch 002

pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology

Time frame:
From Day 332 up to and including Day 661 (Epoch 002)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Any pIMD's During Epoch 002
Percentage of subjectsSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only Group
Percentage of Subjects With Any pIMD's During Epoch 0020.7 (0.0 to 4.1)0.7 (0.0 to 4.1)0.0 (0.0 to 3.0)0.0 (0.0 to 2.7)0.0 (0.0 to 20.6)

Adverse events

Collected over Solicited adverse events were collected during the 7-day follow-up period and unsolicited adverse events during the 30-day follow-up period. Serious adverse events were collected from Day 1 up to Day 661.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sh_NTHi-Mcat_1 Group0/134 (0%)9/134 (6.7%)118/134 (88.1%)
Sh_NTHi-Mcat_3 Group1/134 (0.7%)11/134 (8.2%)125/134 (93.3%)
Sh_NTHi-Mcat_6 Group0/122 (0%)6/122 (4.9%)107/122 (87.7%)
NTHi-Mcat Group0/135 (0%)5/135 (3.7%)125/135 (92.6%)
Shingrix-Only Group0/16 (0%)1/16 (6.3%)—
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only Group
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1340/1340/1220/1351/16
Atrial fibrillationCardiac disorders0/1340/1342/1220/1350/16
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1342/1340/1220/1350/16
COVID-19Infections and infestations0/1340/1341/1220/1350/16
Acute myocardial infarctionCardiac disorders1/1340/1341/1220/1350/16
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1341/1341/1220/1350/16
Cardiac failureCardiac disorders0/1340/1341/1220/1350/16
Tendon disorderMusculoskeletal and connective tissue disorders0/1340/1341/1220/1350/16
Embolism venousVascular disorders0/1340/1341/1220/1350/16
Calculus urinaryRenal and urinary disorders0/1340/1341/1220/1350/16
Most frequent other events
Showing 10 of 108
Most frequent other events
EventSh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only Group
Injection site painGeneral disorders105/134112/13498/122112/135—
FatigueGeneral disorders63/13478/13468/12265/135—
MyalgiaMusculoskeletal and connective tissue disorders48/13464/13456/12267/135—
HeadacheNervous system disorders56/13466/13444/12242/135—
ChillsGeneral disorders40/13441/13440/12226/135—
Gastrointestinal disorderGastrointestinal disorders34/13432/13426/12226/135—
Injection site erythemaGeneral disorders21/13427/13428/12224/135—
Injection site swellingGeneral disorders12/13419/13413/12215/135—
PyrexiaGeneral disorders16/13412/13413/12214/135—
GastritisGastrointestinal disorders0/1343/1340/1220/135—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only GroupTotal
Mean60.7 ± 7.060.9 ± 6.760.5 ± 7.160.0 ± 7.162.4 ± 5.560.6 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Sh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only GroupTotal
Female636658657259
Male716864709282
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sh_NTHi-Mcat_1 GroupSh_NTHi-Mcat_3 GroupSh_NTHi-Mcat_6 GroupNTHi-Mcat GroupShingrix-Only GroupTotal
American Indian Or Alaska Native100102
Black Or African American010102
Not Reported000011
Other4324417
White12913012012911519
08

Study locations

14 sites
  • GSK Investigational Site
    Tallinn, 10117, Estonia
  • GSK Investigational Site
    Tartu, 50106, Estonia
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Helsinki, 00029, Finland
  • GSK Investigational Site
    Jyvaskyla, 40100, Finland
  • GSK Investigational Site
    Tampere, FI-33100, Finland
  • GSK Investigational Site
    Turku, 20100, Finland
  • GSK Investigational Site
    Montpellier cedex 5, 34295, France
  • GSK Investigational Site
    Paris, 75679, France
  • GSK Investigational Site
    Rennes cedex 9, 35033, France
  • GSK Investigational Site
    Pisa, Toscana 56126, Italy
  • GSK Investigational Site
    Verona, Veneto 37134, Italy
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
09

References and documents

Publications

  • Galgani I, Poder A, Jogi R, Anttila VJ, Milleri S, Borobia AM, Launay O, Testa M, Casula D, Grassano L, Tasciotti A, Dozot M, Arora AK. Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial. Hum Vaccin Immunother. 2023 Dec 31;19(1):2187194. doi: 10.1080/21645515.2023.2187194. Epub 2023 Mar 28. PubMed 36974988 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Aug 2020, 16 months.

Results were first posted in Sep 2021, 1 year after primary completion.

Of 12 phase 2 interventional studies under Respiration Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Mar 29, 2019
StartActual
Apr 23, 2019
Primary completionActual
Aug 31, 2020
CompletionActual
Aug 13, 2021
Results first posted
Sep 27, 2021
Last update
Sep 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03894969
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 29, 2019
Start date
Apr 23, 2019
Primary completion
Aug 31, 2020
Completion
Aug 13, 2021
Results posted
Sep 27, 2021
Last update
Sep 23, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion